Home
News
Feed
search engine
by
freefind
advanced
Miscellaneous work on AXA research fund 12-05-2013d0915
2015-01-13
11-27-13 AXA Research Fund Research Information LIFE RISKS (Aging and Long-term care / Emerging biomedical risks) is the closest area to Biomedical Sciences In the majority of areas, clinical orientated to research is out of scope. - Eligible research fields, point 2.3, page 5 AXA Research Fund Through Research Protection Post-Doctoral applications 2014 Guidelines original title Post-Doc-2014 V3 (2) 1.pdf "C:\Users\kurtw_000\Documents\kurt\storage\CIM Research Folder\DR\2013\11-27-13\AXA Research Fund\AXA Research Fund Through Research Protection Post-Doctoral applications 2014 Guidelines.pdf" "C:\Users\kurtw_000\Documents\kurt\storage\CIM Research Folder\DR\2013\11-27-13\AXA Research Fund\AXA Research Fund Through Research Protection Post-Doctoral applications 2014 Guidelines (annotated).pdf" Hi Juan Molina, I am a little bit confused about the information regarding the AXA Postdoctoral Fellowship. I see that there is a deadline for the application on December 16th, but then there is also a deadline for December 1st for an abstract of the research project proposal and an updated CV. Was the original date December 1st, and then later it was moved to December 16th? Or is the fellowship arranged so that some materials are due on December 1st and then some more materials are due on December 16th? requirements -1.5 pages max + referenes about the postdoctoral project -detailed CV (2 pages max + 1/2 page of the most relevant publications) -Career statement (1 page max) -2 letters of recommendation, but I think this is in later rounds (one needs to be written by the Post-Doctoral advisor) grant is 120K euros 35K euro for salary, then 5K (grantee) and 20K (discretion of institution) for other expenses I need to shorten cv so that it fits into 2 pages documents from Maria describing project 11-29-13 -C:\Users\kurtw_000\Documents\kurt\storage\CIM Research Folder\DR\2013\11-29-13 Outline for postdoctoral project (I think it can only be 4-5 paragraphs really for 1.5 pages) -Introduction --Cardiovascular disease is the number one cause of death. --Cardiovascular disease associated with aging --Bone marrow failure associated with aging --Telomerase mitigates the effects of aging. "Telomere syndromes": genetic diseases which result in premature aging and are caused by mutations in genes involved in telomere maintenance (PMID: 22556055) --Telomere shortening (along with genetic and environmental factors) plays a major role in the development of age-associated diseases such as heart disease (PMID: 23022483) --The quantity of short telomeres has been correlated with heart related diseases and lifespan (PMID: 21109027) --Need to study the metabolic factors involved in the effects from telomerase -Mouse models used (what has been done) --Mice with increased telomerase live longer (PMID: 21113150) --AAV TERT gene therapy (specifically AAV9) (PMID: 22585399). achievable therapeutic approach. Delivered via tail vein injection. ---Maria Blasco's lab found that AAV9 does have a tropism for heart cells, and found that 90% of the cells were infected. --Mouse model that mimics the symptoms of aplastic anaemia patients. They delete the TRF1 gene which encodes the TRF1 protein involved in telomere maintenance (PMID: 21346783). The perform a bone marrow transplant from the TRF1 knock-out mice into mice without the mutation. The knockout is actually under the control of a a Cre-recombinase inducible switch. The interferon used is polyinosinic acid-polycytidylic acid (pI:pC). Deletion of these gene causes stem cells in the bone marrow to have very short telomeres, and then there is bone marrow aplasia (PMID: 22932806). --In Maria Blasco's lab, 60 days after treatment, 25% of the aplastic anaemia mice that were treated with a control virus had died, and all of the virus treated mice were still alive. --heart studies ---Maria Blasco's lab has found that treatment with TERT correlated with lower levels of ANP, a polypeptide hormone secreted by heart muscle cells (PMID: 23776857 ), and Foxo3a, a transcription factor involved in cell survival (PMID:23742046). 74% of mice that received TERT gene therapy survived after myocardial infarction. --two models of mice used C57BL6 and FVB/N --myocardial infection is induced by ligating arteries. -What will be done next --Experimental setup to treat two groups of mice and examine many different metabolic factors to identify important pathways. Metabolites can be analyzed by using NMR, and mass spectrometry -Conclusion --use of work: may lead to the discovery of new targets that can be used for regenerative medicine. Now I need to write my career statement which should be one page max Isabel Barthelemy (ibarthelemy@cnio.es) 1. Whittemore K, Sykes K. A microarray method for identifying tumor antigens by screening a tumor cDNA expression library against cancer sera. Hum Vaccin Immunother 2013; 9. Here's some more text as a test ----------- 12-2-13 Maria had me send the application to ibarthelemy@cnio.es In an email from Susa Alcami I was supposed to send the application to formacion@cnio.es Best regards, Kurt Whittemore Graduate Student Arizona State University BIODESIGN INSTITUTE Center for Innovations in Medicine 1001 S McALLISTER AVE TEMPE, AZ 85287 CIM10k and the chips as HT330k 10 mM*11.1/(111.1) = 1 mM Note that the feasibility of component vaccines, instead of whole pathogen vaccines, has been demonstrated.
azim58wiki: